Envío mundial con seguimiento | Aprox. 9–14 días hábiles

Tu carrito

Tu carrito está vacío

Comenzar a explorar

Envío gratuito en pedidos superiores a €500.

Subtotal€0
Proceder al pago
HormonasClínico temprano

Ipamorelin

Investigación publicada y base de evidencia

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a, the ghrelin receptor). It was first characterised in 1998 as the first secretagogue in its class to release growth hormone with potency comparable to GHRP-6 while not significantly elevating ACTH or cortisol above levels seen after GHRH stimulation. Preclinical work has examined longitudinal bone growth, bone mineral content, gastrointestinal motility, nociception and cisplatin-induced weight loss, and human pharmacokinetic-pharmacodynamic modelling has been published. Clinical development advanced to a randomised placebo-controlled phase 2 trial in postoperative ileus after bowel resection, which did not meet its primary endpoint; recent literature consists largely of narrative reviews on unapproved performance-enhancing and therapeutic peptides.

En resumen
  • Ipamorelin es un péptido sintético que estimula la liberación de hormona del crecimiento.
  • Estudios en animales examinaron crecimiento óseo, motilidad intestinal y pérdida de peso.
  • Un ensayo humano en íleo postoperatorio no alcanzó su criterio principal.

18 estudios · 9 desde 2023 · más reciente 2026

Estudios citados
18
Publicados en 2023+
9
Artículo más reciente
2026
Última revisión
oct 2026

Temas recurrentes en la literatura

  • GH secretagogue
  • ghrelin receptor
  • GHS-R1a agonist
  • selective GH release without ACTH/cortisol rise
  • postoperative ileus
  • gastric motility
  • longitudinal bone growth
  • GH-IGF-1 axis
  • anti-doping detection
  • unapproved peptide therapy

Identificadores del compuesto

CAS
170851-70-4
PubChem
9831659

Identidad química

Qué es Ipamorelin, químicamente.

Fórmula molecular
C38H49N9O5
Peso molecular
711.9 g/mol
Número CAS
170851-70-4
PubChem CID
9831659
También escrito como

NNC-26-0161

Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.

La evidencia

18 estudios publicados.

Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.

  1. 01Clínico humano2015

    Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.

    Semenistaya E, et al. · Drug Test Anal · anti-doping administration/excretion study, one volunteer per peptide (ipamorelin n=1, alongside GHRP-1, GHRP-2, GHRP-6 and hexarelin), intranasal, urine collected for 2 days

    After intranasal administration, ipamorelin was extensively metabolised and excreted in urine as the parent peptide together with metabolites, and the ipamorelin (1-4) free acid metabolite was still detected after the parent peptide had disappeared from urine. The abstract reports urinary detection data only, with no clinical or safety outcomes.

  2. 02Clínico humano2014

    Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

    Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group · International Journal of Colorectal Disease · randomised, placebo-controlled phase 2 proof-of-concept trial, n=114 bowel resection patients

    Ipamorelin was reported as well tolerated in patients recovering from bowel resection. It did not produce a statistically significant difference from placebo in time to first tolerated meal.

  3. 03Clínico humano1999

    Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

    Gobburu JV, et al. · Pharmaceutical Research · dose-escalation study in healthy human volunteers

    The analysis characterised dose-proportional kinetics and an elimination half-life of approximately two hours. Pharmacodynamic modelling described episodic growth hormone release across the dose range studied.

  4. 04Animal in vivo2024

    The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism

    Lu Z, et al. · Physiology & Behavior · ferret model of cisplatin-induced emesis and weight loss

    Both GHS-R1a agonists inhibited cisplatin-induced weight loss during the delayed phase. Anti-emetic activity was observed with anamorelin following intracerebroventricular administration, indicating a central site of action that was not reproduced by ipamorelin.

  5. 05Animal in vivo2024

    The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus

    Gouda M, Ganesh CB · Animal Reproduction Science · 21-day dosing (5-30 µg) in the cichlid fish Oreochromis mossambicus

    Ipamorelin acetate produced dose-dependent increases in germ cell development and androgen receptor expression. Luteinizing hormone and 11-ketotestosterone levels were elevated, consistent with action along the hypothalamic-pituitary-testicular axis.

  6. 06Animal in vivo2012

    Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus

    Greenwood-Van Meerveld B, et al. · Journal of Experimental Pharmacology · rodent model of surgically induced gastric dysmotility

    Ipamorelin improved measures of delayed gastric emptying in a rodent postoperative ileus model. The findings were used to support evaluation of the compound for postoperative gastrointestinal dysmotility.

  7. 07Animal in vivo2009

    Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus

    Venkova K, et al. · Journal of Pharmacology and Experimental Therapeutics · rat model of postoperative ileus following abdominal surgery

    Single-dose ipamorelin shortened the time to first bowel movement after surgery. Repeated dosing increased faecal output and food intake relative to control.

  8. 08Animal in vivo2001

    Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.

    Lall S, et al. · Biochem Biophys Res Commun · mice: GH-deficient (lit/lit) and GH-intact, 2-9 weeks of treatment, DEXA

    Ipamorelin raised fat-pad weight relative to body weight in both GH-deficient and GH-intact mice; GH secretagogues, unlike GH itself, increased relative body fat, serum leptin and food intake in GH-intact mice, indicating a GH-independent effect on adiposity.

  9. 09Animal in vivo2001

    The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.

    Andersen NB, et al. · Growth Horm IGF Res · adult female rats, 3 months, glucocorticoid (methylprednisolone) model

    In glucocorticoid-treated rats, co-administration of ipamorelin increased calf-muscle maximum tetanic tension and produced a four-fold higher periosteal bone formation rate than glucocorticoid alone.

  10. 10Animal in vivo1999

    Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats

    Johansen PB, et al. · Growth Hormone & IGF Research · 15-day subcutaneous dosing in rats, multiple dose groups

    Ipamorelin dose-dependently increased longitudinal bone growth and body weight gain over 15 days. Circulating IGF-I and markers of bone resorption were not significantly altered.

  11. 11Animal in vivo1998

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K, et al. · European Journal of Endocrinology · in vitro pituitary assays plus in vivo studies in rats and swine

    Ipamorelin, a pentapeptide, released growth hormone with potency comparable to GHRP-6. Unlike other secretagogues examined, it did not release ACTH or cortisol at levels significantly different from those observed after GHRH stimulation, even at high doses.

  12. 12Revisión2026

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, Awan TM · Sports Medicine · narrative review of approved and unapproved peptide therapies

    The review noted that many unapproved peptides, including growth hormone secretagogues, showed favourable outcomes in animal models while rigorous human safety data remained scarce. The authors set out a framework addressing efficacy uncertainty, product quality and placebo effects.

  13. 13Revisión2026

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

    Dominikowski A, et al. · Frontiers in Endocrinology · narrative review of GH-IGF-1 axis peptides including ipamorelin

    The authors stratified GH-axis peptides by evidence tier and proposed a clinical assessment algorithm for patients self-administering them. Uncertainties around efficacy and potential mitogenic risk were highlighted.

  14. 14Revisión2026

    Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications

    Villegas Meza AD, et al. · JBJS Reviews · structured narrative review of injectable peptides used in sports medicine

    The review concluded that most regenerative and growth hormone peptides remained investigational with uncertain safety profiles. Use was recommended to be limited to approved agents or formal research protocols.

  15. 15Revisión2026

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine

    Tewari K, et al. · The American Journal of Sports Medicine · review of peptide supplements marketed for musculoskeletal recovery and performance

    The authors stated that claimed benefits of emerging peptide supplements remained unsubstantiated by current human trials despite promising animal findings. Cardiovascular and metabolic safety concerns were noted.

  16. 16Revisión2026

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, et al. · The American Journal of Sports Medicine · primer-style review covering commonly encountered injectable peptides

    The review reported that human orthopaedic outcome data remained largely absent despite preclinical signals. The authors concluded that further safety and efficacy research was required before definitive recommendations could be made.

  17. 17Revisión2026

    Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

    Renke G, Chinellato L · International Journal of Molecular Sciences · review of therapeutic peptides across aesthetic, metabolic and endocrine indications

    The review surveyed peptides used in metabolic and endocrine settings, including growth hormone secretagogues. The authors concluded that further study was needed before most newer peptides could be considered safe for human use.

  18. 18Revisión2026

    Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

    Mavrych V, Shypilova I, Bolgova O · Frontiers in Aging · review of nine peptides with proposed applications in ageing biology

    Ipamorelin was discussed among growth hormone modulators examined in the context of healthspan. The authors reported that investigational peptides in this group lacked long-term data and required rigorous clinical validation.

Limitaciones

Lo que esta evidencia no establece.

No randomised controlled trial has demonstrated a clinical benefit of ipamorelin on any efficacy endpoint; the largest human trial, in postoperative ileus, did not separate from placebo, and development for that indication did not proceed. Long-term human safety, effects on body composition, bone or musculoskeletal recovery, and outcomes in non-surgical populations remain unstudied, and the recent literature consists almost entirely of narrative reviews rather than new primary data.

Preguntas comunes sobre la investigación.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide agonist of the growth hormone secretagogue receptor (GHS-R1a). It was characterised in 1998 as the first selective growth hormone secretagogue — selective in the sense that GH release occurred without the ACTH and cortisol response reported for earlier peptides of the same class.

How does it differ from CJC-1295?

The two act on different receptors. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist; CJC-1295 is an analogue of growth hormone-releasing hormone acting at the GHRH receptor. Published human work reports that the two pathways stimulate GH release synergistically, which is the rationale behind the combined vials that appear in the research literature.

How long does it stay in circulation?

Human volunteer data describe a terminal half-life of approximately two hours, a clearance of 0.078 L/h/kg, and a volume of distribution at steady state of 0.22 L/kg, with dose-proportional pharmacokinetics across the range studied.

Disponible en nuestro catálogo

Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.